Fairvalue-Calculator Fairvalue-Calculator
EN DE

China National Medicines Corporation (600511) Fair Value & Analysis

Healthcare · CN · Market cap 21.0B CNY

Price¥27.10
Fair Value¥58.22
Upside+114.8%
Quality88/100
Evidence: Medium Range ¥43.66 – ¥72.07

Fair value as of: Jun 25, 2026

Analysis

China National Medicines Corporation (600511) currently trades at ¥27.10, while our model-based Fair Value estimate is ¥58.22 — implying the stock looks roughly 114.8% undervalued today. We read business quality at 88/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

China National Medicines Corporation Ltd., together with its subsidiaries, engages in pharmaceutical equipment circulation in China. The company also manufactures and sells new drugs; sells Chinese patent medicines drug sales and western medicines, and medical equipment; and offers dental drug and equipment, warehousing, logistics and import and export agency services. It also serves hospitals, retail pharmacies, and medical institutions. The company was founded in 1999 and is based in Beijing, China. China National Medicines Corporation Ltd. operates as a subsidiary of Sinopharm Group Co. Ltd.

Open the full interactive analysis →

Similar stocks

McKesson Corporation (M1CK34) +22% Cencora, Inc (C1CO34) -44% Cardinal Health, Inc (CAH) -49% Sigma Healthcare Limited (SIGGF) -67% Sitka Gold Corp (SIG) -59% Shanghai Pharmaceuticals Holding (601607) +112%

Frequently asked questions

Is China National Medicines Corporation (600511) undervalued?
As of Jun 25, 2026, our model estimates a fair value of ¥58.22 versus a price of ¥27.10 — about +115% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 600511?
Our 21-model fair value for China National Medicines Corporation is ¥58.22 (as of Jun 25, 2026), built from audited fundamentals. The current price is ¥27.10.
What is the quality score of 600511?
China National Medicines Corporation has a Quality Score of 88/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.